Articles related to LEUKEMIA

In this late-breaking abstract from the ASH Annual Meeting & Exhibition, the researches wanted to address the limited understanding of how and when CH develops, what factors govern its behavior, how it interacts with aging, and how these variables relate to malignant progression. Here are the results from analyzing 1,593 blood DNA samples from 385 elderly individuals, each sampled up to 5 times over approximately 13 years.

In ASH Clinical News, Dr. Geoffrey Uy, a professor in the Oncology Division at Washington University School of Medicine in St. Louis, discusses treatment options for a transplant-ineligible patient who has Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL). The patient under review is a 61-year-old female diagnosed with Ph+ ALL who has multiple comorbidities and is not a candidate for allogeneic hematopoietic cell transplantation.

In this series from Blood that tackles four cases studies, the outcomes of AML pediatric patients compared to children with ALL is explored, focusing on the emerging new treatments venetoclax (Venclexta; AbbVie/Genentech), CD33- and CD123-directed CAR T-cell therapy, CD123-directed antibody therapy, and menin inhibitors.

About 75% to 80% of children with pediatric AML have clonal, acquired, somatic cytogenetic abnormalities (CAs) detected. Hematology Advisor briefs the information originally appearing in Genes, which reviews the current knowledge on evaluating pediatric patients based on cytogenetics and molecular subtypes to help match patients to risk-adapted therapies.

Key Points: In two study cohorts, less-intensive therapies increased mortality in each of three risk groups defined by age, comorbidities, and cytogenetics. The differences became nonsignificant after accounting for physician perception of cure, emphasizing the need for a randomized trial.Design: Multicenter retrospective cohort (1,292), 6 institutions, 2008-2012; prospective cohort (695), 13 institutions, 2013 – 2017Connected Content: Fitness for Intensive Chemotherapy: A Continuing Conundrum

Publication: Blood Key Points: The authors identified the following four prognostic indicators that could help control CNS relapse in children with ALL. 1) Prephase dexamethasone treatment, 2) delayed intrathecal therapy, 3) use of total intravenous anesthesia during intrathecal therapy, and 4) flow cytometry examination of diagnostic CSF Design: 7,640 consecutive patients treated on Chinese Children’s Cancer Group ALL-2015 protocol